HAE has a Zacks Rank #3 (Hold) and Value grade of C, with higher valuation multiples across P/E, PEG, and P/B ratios compared to PAHC, positioning it as a less compelling value investment at current levels.
HAE has a Zacks Rank #3 (Hold) with a Value grade of C. While not negative, its higher valuation multiples (forward P/E of 19.67 and P/B of 5.64) compared to GEHC make it less attractive as a value investment option.
Articles that tag HAE but are mainly about other companies.
Listed among key market players in a growing industry with strong market drivers including increased blood donation volumes and therapeutic apheresis demand.
Listed among top market players in the growing therapeutic apheresis sector, well-positioned to capture market share in the expanding USD 8.94 billion market by 2035.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
